PT  - JOURNAL ARTICLE
AU  - Mosley, Mary
ED  - Marso, Steven P.
TI  - LEADER Study: Testing the Cardiovascular Safety of Liraglutide
DP  - 2013 Dec 01
TA  - MD Conference Express
PG  - 14--15
VI  - 13
IP  - 17
4099  - http://mdc.sagepub.com/content/13/17/14.short
4100  - http://mdc.sagepub.com/content/13/17/14.full
AB  - Liraglutide, an analogue for human glucagon-like peptide 1, is approved for patients with type 2 diabetes mellitus and is associated with HbA1C reductions of 1.0% to 1.5% and moderate weight loss. Diabetes is associated with a 2-fold increased risk of cardiovascular (CV) events. The ongoing Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A Long Term Evaluation trial [LEADER; NCT01179048] is evaluating the CV safety of liraglutide, in accordance with requirements of the United States Food and Drug Administration.